M. Kathryn Fink
Known title: VP, Chief HR OfficerCIK: 0001663095
Associated companies
Transaction History
| SYK | ▼ Sell | Tax Withholding | 111 | $36K | 8/1/2026 | View on chart |
| SYK | ▼ Sell | Open Market | 5,220 | $1.5M | 5/11/2026 | View on chart |
| SYK | ▼ Sell | Open Market | 3,500 | $992K | 5/11/2026 | View on chart |
| SYK | ▼ Sell | Tax Withholding | 16,362 | $4.8M | 5/8/2026 | View on chart |
| SYK | ▲ Buy | Option Exercise | 11,850 | $2.1M | 5/8/2026 | View on chart |
| SYK | ▲ Buy | Option Exercise | 9,732 | $1.5M | 5/8/2026 | View on chart |
| SYK | ▲ Buy | Option Exercise | 150 | $0 | 3/21/2026 | View on chart |
| SYK | ▼ Sell | Tax Withholding | 2,064 | $693K | 3/21/2026 | View on chart |
| SYK | ▲ Buy | Grant | 5,220 | $0 | 3/9/2026 | View on chart |
| SYK | ▼ Sell | Tax Withholding | 37 | $13K | 12/16/2025 | View on chart |
| SYK | ▲ Buy | Grant | 917 | $0 | 8/5/2025 | View on chart |
| SYK | ▲ Buy | Option Exercise | 102 | $0 | 3/21/2025 | View on chart |
| SYK | ▼ Sell | Tax Withholding | 1,707 | $639K | 3/21/2025 | View on chart |
| SYK | ▲ Buy | Grant | 4,189 | $0 | 3/10/2025 | View on chart |
| SYK | ▼ Sell | Open Market | 134 | $50K | 9/17/2024 | View on chart |
| SYK | ▼ Sell | Open Market | 1,530 | $569K | 9/17/2024 | View on chart |
| SYK | ▼ Sell | Open Market | 422 | $157K | 9/17/2024 | View on chart |
| SYK | ▼ Sell | Open Market | 258 | $93K | 9/17/2024 | View on chart |
| SYK | ▼ Sell | Open Market | 1,336 | $484K | 9/17/2024 | View on chart |
| SYK | ▼ Sell | Open Market | 474 | $172K | 9/17/2024 | View on chart |
| SYK | ▼ Sell | Open Market | 635 | $232K | 9/17/2024 | View on chart |
| SYK | ▼ Sell | Open Market | 487 | $178K | 9/17/2024 | View on chart |
| SYK | ▼ Sell | Open Market | 931 | $342K | 9/17/2024 | View on chart |
| SYK | ▼ Sell | Open Market | 460 | $169K | 9/17/2024 | View on chart |
| SYK | ▼ Sell | Open Market | 680 | $251K | 9/17/2024 | View on chart |
| SYK | ▲ Buy | Option Exercise | 7,347 | $900K | 9/16/2024 | View on chart |
| SYK | ▼ Sell | Open Market | 2,121 | $785K | 9/13/2024 | View on chart |
| SYK | ▼ Sell | Tax Withholding | 140 | $47K | 5/1/2024 | View on chart |
| SYK | ▲ Buy | Option Exercise | 83 | $0 | 3/21/2024 | View on chart |
| SYK | ▼ Sell | Tax Withholding | 1,425 | $503K | 3/21/2024 | View on chart |
| SYK | ▲ Buy | Grant | 3,463 | $0 | 3/11/2024 | View on chart |
| SYK | ▼ Sell | Tax Withholding | 140 | $42K | 5/1/2023 | View on chart |
| SYK | ▲ Buy | Option Exercise | 46 | $0 | 3/21/2023 | View on chart |
| SYK | ▼ Sell | Tax Withholding | 752 | $208K | 3/21/2023 | View on chart |
| SYK | ▲ Buy | Grant | 1,664 | $0 | 3/7/2023 | View on chart |
| SYK | ▼ Sell | Open Market | 3,417 | $879K | 1/11/2023 | View on chart |
| SYK | ▼ Sell | Open Market | 346 | $90K | 1/11/2023 | View on chart |
| SYK | ▼ Sell | Open Market | 116 | $30K | 1/11/2023 | View on chart |
| SYK | ▼ Sell | Open Market | 131 | $34K | 1/11/2023 | View on chart |
| SYK | ▼ Sell | Open Market | 1,403 | $363K | 1/11/2023 | View on chart |
| SYK | ▼ Sell | Open Market | 1,158 | $297K | 1/11/2023 | View on chart |
| SYK | ▲ Buy | Option Exercise | 1,397 | $130K | 1/10/2023 | View on chart |
| SYK | ▲ Buy | Option Exercise | 5,174 | $500K | 1/10/2023 | View on chart |
| SYK | ▼ Sell | Open Market | 3,536 | $919K | 1/9/2023 | View on chart |
| SYK | ▼ Sell | Open Market | 340 | $75K | 11/2/2022 | View on chart |
| SYK | ▲ Buy | Option Exercise | 317 | $0 | 5/1/2022 | View on chart |
| SYK | ▼ Sell | Tax Withholding | 141 | $34K | 5/1/2022 | View on chart |
| SYK | ▼ Sell | Tax Withholding | 811 | $217K | 3/21/2022 | View on chart |
| SYK | ▲ Buy | Option Exercise | 2,745 | $0 | 3/21/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Stryker's $400M Robotics Deal and FDA Clearance of Sonopet 3
Stryker announced a $400 million agreement to expand its robotics portfolio, detailing the technologies and capabilities it will acquire. In a separate update, the company received FDA clearance for the Sonopet 3, a new tool within its surgical platform. Both moves broaden Stryker’s product range and may support future revenue growth. The developments come as the stock trades near its recent support level.
Stryker's $400M Robotics Deal and FDA Clearance of Sonopet 3. Stryker announced a $400 million agreement to expand its robotics portfolio, detailing the technologies and capabilities it will acquire. In a separate update, the company received FDA clearance for the Sonopet 3, a new tool within its surgical platform. Both moves broaden Stryker’s product range and may support future revenue growth. The developments come as the stock trades near its recent support level.